{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red33\green33\blue33;
\red37\green37\blue37;
\red187\green187\blue187;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red255\green248\blue96;
\red119\green119\blue119;
\red203\green203\blue203;
\red245\green245\blue245;
\red204\green204\blue204;
\red228\green231\blue232;
\red255\green255\blue102;
\red80\green80\blue80;
\red51\green51\blue51;
\red56\green124\blue43;
\red246\green246\blue246;
\red151\green151\blue151;
\red254\green254\blue0;
\red0\green114\blue54;
\red233\green233\blue233;
\red112\green112\blue112;
\red106\green144\blue39;
\red21\green137\blue21;
\red239\green122\blue2;
\red247\green247\blue247;
\red232\green233\blue232;
\red249\green249\blue249;
\red249\green250\blue251;
\red181\green79\blue104;
\red102\green102\blue102;
\red240\green248\blue255;
\red127\green127\blue127;
\red255\green255\blue204;
\red255\green204\blue0;
\red255\green255\blue174;
\red183\green242\blue206;
\red255\green194\blue211;
\red61\green61\blue61;
\red227\green227\blue227;
\red240\green240\blue240;
\red105\green105\blue105;
\red20\green93\blue164;
\red238\green238\blue238;
\red182\green231\blue243;
\red118\green118\blue118;
\red204\green255\blue255;
\red223\green223\blue223;
\red239\green239\blue239;
\red236\green236\blue236;
\red255\green255\blue198;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red153\green153\blue153;
\red71\green120\blue194;
\red229\green243\blue255;
\red179\green218\blue255;
\red188\green41\blue30;
\red190\green237\blue228;
\red190\green190\blue252;
\red255\green210\blue183;
\red221\green195\blue236;
\red68\green68\blue68;
\red214\green214\blue214;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 Source Sans Pro;}{
\f6 serif;}{
\f7 Courier New;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid-1514688488\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid558290014}
}
{\*\listoverridetable
{\*\listoverride{\listid558290014\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf21 \f0 \i0 \fs18 
{\b1 \cf21 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Cedars Sinai Medical Center v. Quest Diagnostic Incorporated, Not Reported in Fed....
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_28}{\*\bkmkend co_document_28}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I9d72eec0688e11e88808c81b5a222cba_Target}{\*\bkmkend I9d72eec0688e11e88808c81b5a222cba_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_28}{\*\bkmkend co_readingModeKC_28}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_28}{\*\bkmkend co_readingModeCitatorFlag_28}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I9d72eec0688e11e88808c81b5a222cba&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_28}{\*\bkmkend co_readingModeNegativeTreatment_28}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I83cfc98025a011eba094ed6df7a8b3f2/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI83cfc98025a011eba094ed6df7a8b3f2%26ss%3D2044666998%26ds%3D2052354596%26origDocGuid%3DI9d72eec0688e11e88808c81b5a222cba&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=b23d13c980c84be38b0fc9fe01929cbe&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Masimo Corporation v. Apple Inc.
}
{\b0 \cf23 \f2 \i0 \fs16 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
C.D.Cal., 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
October 13, 2020
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2018 WL 2558388
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, C.D. California.
\par 
}
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
CEDARS SINAI MEDICAL CENTER
\par 
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
QUEST DIAGNOSTIC INCORPORATED
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Case No. CV 17\u8211\'3f5169\u8211\'3fGW(FFMx)
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Filed 02/27/2018
\par 
}
}
}
}
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_28}{\*\bkmkend co_attorneysAndLawFirms_28}
{\b1 \cf18 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0180086901&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Edward G. Poplawski
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0484499301&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lisa D. Zang
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0334898601&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Olivia M. Kim
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Wilson Sonsini Goodrich and Rosati PC, Los Angeles, CA, for Cedars Sinai Medical Center.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0419770501&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alexandra Olwen Fellowes
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0380583801&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jonathan D. Loeb
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0499421999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Angela M. Gandhi
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dechert LLP, Mountain View, CA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0216734401&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher Steven Ruhland
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0466300801&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Anna Quynh Do
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dechert LLP, Los Angeles, CA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0126764101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Diane S. Danoff
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Pro Hac Vice, Dechert LLP, Philadelphia, PA, for Quest Diagnostic Incorporated.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_28}{\*\bkmkend co_opinion_28}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4adfe282065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4adfe282065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4af28021065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4af28021065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4af28021065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4af28021065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb800 
PROCEEDINGS: IN CHAMBERS\u8212\'3fFINAL RULING ON DEFENDANT QUEST\rquote S MOTION TO DISMISS CEDARS\u8211\'3fSINAI\rquote S SECOND AMENDED COMPLAINT [26]
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0151975701&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
GEORGE H. WU
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, UNITED STATES DISTRICT JUDGE
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_28}{\*\bkmkend co_pp_sp_999_1_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Attached hereto is the final ruling on the Defendant\rquote s Motion to Dismiss. Pursuant to the portion of that decision concerning the patent infringement cause of action, the Court sets a scheduling conference for March 8, 2018 at 8:30 a.m., for which the parties may appear telephonically. The conference will concern expedited discovery and claim construction schedule solely as it relates to the claim term \u8220\'3fan assay\u8221\'3f as it appears in Claims 3, 4, 9, and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The parties will file a joint report by March 6 with either agreed upon dates or the respective versions of the dates proposed by each side.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4af36a81065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4af36a81065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4af36a81065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4af36a81065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
I. Background
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff Cedars\u8211\'3fSinai brings this action against Defendants Quest Diagnostics, Inc. and Quest Diagnostics Nichols Institute (collectively, \u8220\'3fQuest\u8221\'3f) alleging four claims: 1) trade secret misappropriation, in violation of the Defend Trade Secrets Act (\u8220\'3fDTSA\u8221\'3f), 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=18USCAS1836&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
18 U.S.C. \u167\'3f 1836
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 2) trade secret misappropriation, in violation of the California Uniform Trade Secrets Act (\u8220\'3fCUTSA\u8221\'3f), 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000200&cite=CACIS3426&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Code \u167\'3f 3426
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 3) breach of contract; and 4) patent infringement. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See generally
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Second Amended Complaint (\u8220\'3fSAC\u8221\'3f), Docket No. 23. Quest moves to dismiss the SAC in its entirety and, in the alternative, moves for a more definite statement regarding Cedars\u8211\'3fSinai\rquote s alleged trade secrets. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See generally
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion to Dismiss SAC (\u8220\'3fMotion\u8221\'3f), Docket No. 26\u8211\'3f1; Reply to Opposition to Motion (\u8220\'3fReply\u8221\'3f), Docket No. 37. Cedars\u8211\'3fSinai opposes the Motion. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See generally
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Opposition to Motion (\u8220\'3fOpp\rquote n\u8221\'3f), Docket No. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cedars\u8211\'3fSinai alleges the following relevant facts:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cedars\u8211\'3fSinai is a nonprofit academic medical center. SAC \u182\'3f 16. It has supported decades of research into the pathophysiology of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Irritable Bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Syndrome (\u8220\'3fIBS\u8221\'3f) and development of diagnostics and treatments for IBS, licensing the results of this research to generate revenue to fund its research operations. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Briefly, Cedars\u8211\'3fSinai: 1) discovered that the detection of particular antibodies above control levels\u8212\'3fincluding anti\u8211\'3fvinculin and \u8220\'3fanti-CdtB\u8221\'3f antibodies\u8212\'3findicates the presence of IBS, 2) that the symptoms of IBS may be attributed to small intestinal bacterial overgrowth (\u8220\'3fSIBO\u8221\'3f), and 3) that SIBO may be treated with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2a1cd475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
rifaximin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 25. At the time of the Cedars\u8211\'3fSinai team\rquote s discovery, there was no existing diagnostic test for IBS using anti-vinculin antibodies\u8212\'3for any other type of antibodies\u8212\'3fon the market. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 31. Beginning on February 11, 2009, Cedars\u8211\'3fSinai filed a series of provisional patent applications for blood tests for IBS based on these discoveries that ultimately matured into 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Patent No. 9,702,884 (\u8220\'3f \u8217\'3f884 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, in addition to other patents in the United States and in foreign jurisdictions. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 33.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In November 2013, Cedars\u8211\'3fSinai and Quest opened discussions about licensing Cedars\u8211\'3fSinai\rquote s diagnostic technology to commercialize the research. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 34. On or about November 24, 2013, the parties entered into \u8220\'3fConfidentiality Obligations\u8221\'3f to facilitate those discussions. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. During the course of these discussions, Cedars\u8211\'3fSinai disclosed \u8220\'3fconfidential details\u8221\'3f of Cedars\u8211\'3fSinai\rquote s diagnostic technology. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 37, 38, 41. Additionally, Cedars\u8211\'3fSinai provided to Quest a confidential presentation
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012044666998_ID0EQHAC_28}{\*\bkmkend co_fnRef_B00012044666998_ID0EQHAC_28}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012044666998_28" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 36), unpublished patent applications (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 37, 43), a confidential manuscript (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 40), and confidential market research (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 42). On or about December 23, 2014, after a year of discussions and the receipt of the aforementioned materials, Quest informed Cedars\u8211\'3fSinai that it was not interested in pursuing the licensing agreement further. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 44.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_28}{\*\bkmkend co_pp_sp_999_2_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Cedars\u8211\'3fSinai subsequently learned that on or about July 9, 2015, Quest filed an application to register a trademark for \u8220\'3fmedical diagnostic testing services; medical information services.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 47. \u8220\'3fOn information and belief, therefore, as of and before July 9, 2015, Quest was creating, designing, developing, and/or using an IBS assay and/or doing IBS testing and/or making preparations for delivery of IBS services and the use of an IBS assay or diagnostic.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In April 2017, Cedars\u8211\'3fSinai learned that Quest was performing IBS diagnostic testing services under the trademark it applied for in July 2015. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 48. \u8220\'3fUpon information and belief, Quest\rquote s diagnostic IBS testing services and IBS testing are based on unauthorized and unlawful use of Cedars\u8211\'3fSinai\rquote s patented inventions, trade secrets, and other confidential information subject to the Confidentiality Obligations, without any authorization by or compensation to Cedars\u8211\'3fSinai.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 49.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4af8e8c1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4af8e8c1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4af8e8c1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4af8e8c1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
II. Legal Standard
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4af8e8c1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4af8e8c1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Motion to Dismiss (Rule 12(b)(6))
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Under Rule 12(b)(6), a defendant may move to dismiss for failure to state a claim upon which relief can be granted. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A complaint may be dismissed for failure to state a claim for one of two reasons: (1) lack of a cognizable legal theory; or (2) insufficient facts under a cognizable legal theory. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_555&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_555" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bell Atl. Corp. v. Twombly
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 544, 555 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015647475&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1104&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1104" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mendiondo v. Centinela Hosp. Med. Ctr.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 521 F.3d 1097, 1104 (9th Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fDismissal under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is appropriate only where the complaint lacks a cognizable legal theory or sufficient facts to support a cognizable legal theory.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In deciding a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion, a court \u8220\'3fmay generally consider only allegations contained in the pleadings, exhibits attached to the complaint, and matters properly subject to judicial notice.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011437883&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_763&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_763" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Swartz v. KPMG LLP
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 476 F.3d 756, 763 (9th Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court must construe the complaint in the light most favorable to the plaintiff, accept all allegations of material fact as true, and draw all reasonable inferences from well-pleaded factual allegations. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002485078&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_896&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_896" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gompper v. VISX, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 298 F.3d 893, 896 (9th Cir. 2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001781935&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_988&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_988" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sprewell v. Golden State Warriors
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 266 F.3d 979, 988 (9th Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
amended on denial of reh\rquote g
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001590859&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
275 F.3d 1187 (9th Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1996076158&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_337" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cahill v. Liberty Mutual Ins. Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 80 F.3d 336, 337\u8211\'3f38 (9th Cir. 1996)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court is not required to accept as true legal conclusions couched as factual allegations. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018848474&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_678&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_678" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ashcroft v. Iqbal
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 556 U.S. 662, 678 (2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Where a plaintiff facing a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion has pleaded \u8220\'3ffactual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged,\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the motion should be denied. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031496547&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1191&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1191" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sylvia Landfield Trust v. City of Los Angeles
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 729 F.3d 1189, 1191 (9th Cir. 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But if \u8220\'3fthe well-pleaded facts do not permit the court to infer more than the mere possibility of misconduct, the complaint has alleged \u8211\'3f but it has not show[n] ... the pleader is entitled to relief.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018848474&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_679&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_679" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Iqbal
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 556 U.S. at 679
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4afc1d11065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4afc1d11065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4afc1d11065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4afc1d11065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
B. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Motion for a More Definite Statement (
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(e)
}}}
\sb200 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
)
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fA party may move for a more definite statement of a pleading to which a responsive pleading is allowed but which is so vague or ambiguous that the party cannot reasonably prepare a response.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fCourts have held that a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion is proper only where the complaint is 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
so indefinite that defendant cannot ascertain the nature of the claim
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 being asserted.\u8221\'3f O\rquote Connell & Stevenson, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Fed. Civ. Proc. Before Trial, California & 9th Circuit Edition
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fFederal Practice Guide\u8221\'3f), \u167\'3f 9:347 (Rutter Grp. 2017) (emphasis in original). The motion \u8220\'3fmust point out the defects complained of and the details desired.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4afd5591065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4afd5591065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4afd5591065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4afd5591065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
III. Discussion
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4afd5591065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4afd5591065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
First and Second Claims: Trade Secret Misappropriation
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To state a claim for trade secret misappropriation under the CUTSA,
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
a plaintiff must allege that: (1) the plaintiff owned a trade secret; (2) the defendant misappropriated the trade secret; and (3) the defendant\rquote s actions damaged the plaintiff.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036274326&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Autodesk, Inc. v. ZWCAD Software Co., Ltd.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, [Case] No. 14\u8211\'3f1409, 2015 WL 2265479, at *5 (N.D. Cal. May 13, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citation omitted). The elements of misappropriation under the DTSA are similar to those under the CUTSA. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Compare
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=18USCAS1839&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=SP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_362c000048fd7" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
18 U.S.C. \u167\'3f 1839(5)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
with
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000200&cite=CACIS3426.1&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=SP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Code \u167\'3f 3426.1(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_28}{\*\bkmkend co_pp_sp_999_3_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042176661&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Space Data Corp. v. X
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 16\u8211\'3f3260, 2017 WL 3007078, at *2 (N.D. Cal. July 14, 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fA \u8216\'3ftrade secret\u8217\'3f is defined as information that: (1) derives independent economic value from not being generally known to the public; and (2) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041351608&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gatan, Inc. v. Nion Company
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 15\u8211\'3f1862, 2017 WL 1196819, at * 6 (N.D. Cal. Mar. 31, 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000200&cite=CACIS3426.1&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Code \u167\'3f 3426.1
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1974127179&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_476&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_476" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Kewanee Oil Co. v. Bicron Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 416 U.S. 470, 476 (1974)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe subject of a trade secret must be secret, and must not be of public knowledge or of a general knowledge in the trade or business.\u8221\'3f). Because the pleading standards of Cedars\u8211\'3fSinai\rquote s DTSA and CUTSA claims are the same, the Court will analyze those two claims together. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043193534&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rockwell Collins, Inc. v. Wallace
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 17\u8211\'3f1369\u8211\'3fAG\u8211\'3f(JCGx), 2017 WL 5502775, at *2 (C.D. Cal. Nov. 20, 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (analyzing DTSA and CUTSA claims together on a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion to dismiss).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022044666998_ID0EQLAE_28}{\*\bkmkend co_fnRef_B00022044666998_ID0EQLAE_28}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022044666998_28" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties halfheartedly suggest that trade secret misappropriation claims are subject to a heightened pleading standard. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion at 13\u8211\'3f14; Opp\rquote n at 10. Although the parties raise the issue only in the context of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fand not 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8212\'3fthe Court finds that it is necessary to address it here as a heightened pleading standard would necessarily impact the Court\rquote s analysis of both the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6) and Rule 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issues. The dearth of authority provided by the parties required the Court to conduct its own research, which revealed that the issue is unsettled. After a review of cases in this judicial district, the Court would find that a heightened pleading standard is not applicable to Plaintiff\rquote s statutory trade secret misappropriation claims and will not apply one here.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court\rquote s research revealed as an initial matter that courts often describe the adequacy of trade secret pleadings by using the terms \u8220\'3fsufficient particularity\u8221\'3f and \u8220\'3freasonable particularity,\u8221\'3f but it is unclear whether there is a meaningful difference between the two. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Some courts use only one or the other while other courts use them interchangeably. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043696390&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Manchester v. Sivantos GMBH
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 17\u8211\'3f5309\u8211\'3fODW\u8211\'3f(JEMx), 2018 WL 587849, at *3 (C.D. Cal. Jan. 29, 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (using \u8220\'3fsufficient particularity\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041580985&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teledyne Risi, Inc. v. Martin\u8211\'3fBaker Aircraft Co., Ltd.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 15\u8211\'3f7936\u8211\'3fSJO\u8211\'3f(GJSx), 2016 WL 8857029, at *7 (C.D. Cal. Feb. 2, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (using \u8220\'3freasonable particularity\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040230274&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Jun\u8211\'3fEn Enter. v. Lin
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 12\u8211\'3f2734\u8211\'3fPSG\u8211\'3f(Ssx), 2012 WL 12886499, at *3 (C.D. Cal. Oct. 17, 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (using terms interchangeably); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039252058&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
TMC Aerospace, Inc. v. Elbit Systems of America LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 15\u8211\'3f7595\u8211\'3fAB\u8211\'3f(Ex), 2016 WL 3475322, at *4 (C.D. Cal. Jan. 29, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (using terms interchangeably); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040340109&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sms Signature Cars v. Connects Mktg. LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 12\u8211\'3f1300\u8211\'3fJVS\u8211\'3f(ANx), 2013 WL 12138992, at *2\u8211\'3f3 (C.D. Cal. May 15, 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (using terms interchangeably). For its purposes here the Court will consider the two terms to be functionally equivalent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court finds cases applying a heightened standard unpersuasive. Two of the cases find a heightened pleading standard based on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000201&cite=CACPS2019.210&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Proc. Code \u167\'3f 2019.210
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which requires a plaintiff to describe trade secrets with \u8220\'3freasonable particularity\u8221\'3f prior to the initiation of discovery. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039252058&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
TMC Aerospace
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2016 WL 3475322 at *4
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040340109&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sms Signature Cars
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2013 WL 12138992 at *3
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000201&cite=CACPS2019.210&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Proc. Code \u167\'3f 2019.210
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 says nothing of pleading and by its very terms is limited to the initiation of discovery. Furthermore, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000201&cite=CACPS2019.210&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Proc. Code \u167\'3f 2019.210
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a California statute and thus could not apply to DTSA claims. To the contrary, the DTSA\u8212\'3fenacted in 2016\u8212\'3fmakes no mention of any heightened pleading standard. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=l&pubNum=1077005&cite=UUID(IA41A87300D-C111E694ABA-2369149DAF1)&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=SL&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pub. L. No. 114\u8211\'3f153, 130 Stat. 376 (2016).
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Finally, the Court notes that in an unpublished decision, the Ninth Circuit stated that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000201&cite=CACPS2019.210&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Proc. Code \u167\'3f 2019.210
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not apply at the pleading stage. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033467060&pubNum=0006538&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_6538_803&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_803" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Meggitt San Juan Capistrano, Inc. v. Nie Yongzhong
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 575 Fed.Appx. 801, 803 (9th Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAppellants cite no state authority for the proposition that Meggitt SJC should have identified the particular trade secrets 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
at the pleading stage
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rather, the authorities on which they rely simply require a plaintiff to identify a trade secret \u8220\'3fwith reasonable particularity\u8221\'3f prior to commencing discovery.\u8221\'3f) (emphasis in original).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_28}{\*\bkmkend co_pp_sp_999_4_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court finds persuasive the reasoning of cases that decline to apply a heightened pleading standard to CUTSA or DTSA claims. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g., Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043193534&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rockwell
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 5502775 at *2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that the \u8220\'3fparticularity\u8221\'3f requirement from Rule 9 does not apply to DTSA claims and that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000201&cite=CACPS2019.210&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Proc. Code \u167\'3f 2019.210
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not apply to pleadings); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033766934&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
New Show Studio LLC v. Needle
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 14\u8211\'3f01250\u8211\'3fCAS\u8211\'3f(MRWx), 2014 WL 2988271, at *9 (C.D. Cal. June 30, 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000201&cite=CACPS2019.210&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cal. Civ. Proc. Code \u167\'3f 2019.210
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fdoes not provide grounds for dismissing a trade secret claim at the pleading stage\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042176661&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Space Data Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 3007078 at *3
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (declining to apply a heightened pleading standard to CUTSA and DTSA claims because \u8220\'3fthe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000201&cite=CACPS2019.210&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[Cal. Civ. Proc. Code] \u167\'3f 2019.210
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 statement is an issue separate from [defendant\rquote s] motion to dismiss\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The two cases cited by Quest do not support requiring a heightened pleading standard. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion at 13. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998174029&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Imax Corp. v. Cinema Technologies, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 152 F.3d 1161 (9th Cir. 1998)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the appellate court reviewed a district court\rquote s decision at the summary judgment stage and thus did not elucidate what is required of trade secret misappropriation pleadings. And in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031734496&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rovince
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
International Corp. v. Preston
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 13\u8211\'3f3527\u8211\'3fCAS\u8211\'3f(PJWx), 2013 WL 5539430 (C.D. Cal. Oct. 7, 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the court did not explicitly address whether a heightened pleading standard applies to trade secret misappropriation claims. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033766934&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
New Show Studio
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2014 WL 2988271 at *9
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rovince
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not stand for the proposition that plaintiffs are required to identify their trade secrets with particularity).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In sum, the Court finds that in the context of both 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6) and Rule 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, pleadings for trade secret misappropriation should be held to the standard articulated in Rule 8(a)(2). 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR8&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 8(a)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fA pleading that states a claim for relief must contain ... a short and plain statement of the claim showing that the pleader is entitled to relief\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042176661&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Space Data Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 3007078 at *3
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (applying the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR8&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 8
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 standard in determining whether the identification of trade secrets in a complaint is adequate). Accordingly, the Court will not apply a heightened pleading standard here.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032044666998_ID0EF1AE_28}{\*\bkmkend co_fnRef_B00032044666998_ID0EF1AE_28}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032044666998_28" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b0a9c01065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b0a9c01065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa200 \sb400 
1. The SAC Adequately Pleads Trade Secret Misappropriation
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Quest contends that no trade secrets exist because all the information allegedly provided to it by Cedars\u8211\'3fSinai was publicly disclosed. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion at 3\u8211\'3f7 (detailing disclosures). Specifically, Quest goes to great lengths to show that the materials Cedars\u8211\'3fSinai identifies as its trade secrets were publicly disclosed through patent applications and the PLoS One article.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042044666998_ID0E62AE_28}{\*\bkmkend co_fnRef_B00042044666998_ID0E62AE_28}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042044666998_28" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion at 9\u8211\'3f13. These disclosures ostensibly include testing methods for IBS by measuring anti-vinculin and anti\u8211\'3fCdtB, methods for validating these tests, and Cedars\u8211\'3fSinai\rquote s assessment of the potential market for these tests. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Cedars\u8211\'3fSinai acknowledges that it disclosed some information publicly, but disputes that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
all
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the information it provided to Quest was disclosed in Cedars\u8211\'3fSinai\rquote s patent applications and the PLoS ONE article. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Opp\rquote n at 7\u8211\'3f9.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_28}{\*\bkmkend co_pp_sp_999_5_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Second Amended Complaint alleges that in the course of confidential communications, Cedars\u8211\'3fSinai provided Quest a confidential presentation (SAC \u182\'3f 36), unpublished patent applications (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 37, 43), a confidential manuscript of a paper to the New England Journal of Medicine (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 40), technical information on two possible test methods not disclosed in the patent applications (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 41), a validation method (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), and a confidential IBS diagnostic market research presentation (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 42). The Court accepts that Cedars\u8211\'3fSinai publicly disclosed some information about its research of IBS diagnostic techniques, but cannot conclude, on a motion to dismiss, that Cedars\u8211\'3fSinai disclosed 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
everything
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 about its research in IBS diagnostics. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036705724&pubNum=0007903&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_7903_1191&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1191" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
T\u8211\'3fMobile USA, Inc. v. Huawei Device USA, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 115 F. Supp. 3d 1184, 1191\u8211\'3f92 (W.D. Wash. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fIt is simple enough to conclude, based on this host of disclosures, that T\u8211\'3fMobile publicly disclosed much about Tappy. It is another matter entirely to conclude, especially given the limits of a motion to dismiss for failure to state a claim, that T\u8211\'3fMobile disclosed 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
everything
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 about Tappy, including trade secret information.\u8221\'3f) (emphasis in original). The arguments and counterarguments presented by the parties in this case regarding the scope of Cedar\u8211\'3fSinai\rquote s trade secrets and its disclosures present highly factual issues that are not properly decided on a motion to dismiss.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052044666998_ID0EPCAG_28}{\*\bkmkend co_fnRef_B00052044666998_ID0EPCAG_28}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052044666998_28" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 It is not appropriate for the Court to go through every detail of each of these confidential communications, as well as the published patent applications and the PLoS ONE article, to determine whether or not 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
every
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 alleged trade secret was publicly disclosed. Notably, patent applications and scientific articles are highly technical and would likely require expert testimony to decipher. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036705724&pubNum=0007903&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_7903_1192&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1192" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1192
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAt the threshold, the court is in no position on a motion to dismiss to sift through patent applications and discern whether they fully disclose everything about Tappy.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039341461&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Emazing Lights LLC v. De Oca
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. 15\u8211\'3f1561\u8211\'3fAG\u8211\'3f(Ex), 2016 WL 3658945, at *3 (C.D. Cal. Jan. 7, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (rejecting defendants\u8217\'3f arguments that plaintiff destroyed any relevant trade secrets by publicly disclosing them in its patent and patent application). Furthermore, even if the Court were inclined to engage in the factual inquiry of comparing Cedar\u8211\'3fSinai\rquote s public disclosures with Quest\rquote s IBS diagnostic technology, it has no information regarding that technology that it could use to make such a comparison.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In summary, the Court would find that Cedars\u8211\'3fSinai has adequately pleaded misappropriation of trade secrets claims under both the DTSA and CUTSA. Cedars\u8211\'3fSinai has alleged that it owns trade secrets relating to its research on IBS diagnostic techniques. Additionally, Cedars\u8211\'3fSinai has alleged that Quest misappropriated these trade secrets (SAC \u182\'3f\u182\'3f 49, 56) and that Quest\rquote s actions have damaged Cedars\u8211\'3fSinai (SAC \u182\'3f 57). Thus, all elements of a trade secret misappropriation claim are plausibly alleged. Accordingly, the Court would deny the Motion in as much as it seeks to dismiss Cedars\u8211\'3fSinai\rquote s first and second claims for relief.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b1152c1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b1152c1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b1152c1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b1152c1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb400 
2. The SAC Adequately Identifies Cedars\u8211\'3fSinai\rquote s Trade Secrets
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In the alternative, Quest argues that Cedars\u8211\'3fSinai has failed to identify its trade secrets with reasonable particularity and moves for a more definite statement pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00062044666998_ID0EFHAG_28}{\*\bkmkend co_fnRef_B00062044666998_ID0EFHAG_28}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00062044666998_28" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion at 13\u8211\'3f15. Case law indicates that the level of detail required in trade secret pleadings is not high. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039252058&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
TMC Aerospace,
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2016 WL 3475322 at *5
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding \u8220\'3fproprietary design drawings, manufacturing techniques, and manufacturing equipment including moulds and jigs\u8221\'3f as an adequate description of trade secrets); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036274326&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Autodesk
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2015 WL 2265479 at *5
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding \u8220\'3fsource code which comprises AutoCAD 2007 and 2008 is a trade secret, including those portions of code that underlie the commands, interfaces and program files associated with the dozens of specific features which were wrongfully acquired and used in defendants\u8217\'3f ZWCAD+ 2012 and 2014 programs\u8221\'3f as adequate). Courts have acknowledged that requiring plaintiffs to spell out their trade secrets in great detail would risk public disclosure, the very thing plaintiffs are seeking to prevent. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1968111402&pubNum=0000225&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_225_252&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_225_252" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diodes, Inc. v. Franzen
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 260 Cal. App. 2d 244, 252 (1968)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fOne who seeks to protect his trade secrets from wrongful use or disclosure does not have to spell out the details of the trade secret to avoid a demurrer to a complaint. To so require would mean that the complainant would have to destroy the very thing for which he sought protection by making public the secret itself.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036274326&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Autodesk
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2015 WL 2265479 at *6
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[C]ourts are \u8216\'3fin general agreement that trade secrets need not be disclosed in detail in a complaint alleging misappropriation for the simple reason that such a requirement would result in public disclosure of the purported trade secrets.\u8217\'3f \u8221\'3f) (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1991035555&pubNum=0000345&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_345_636&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_345_636" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Leucadia, Inc. v. Applied Extrusion Technologies, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 755 F. Supp. 635, 636 (D. Del. 1991)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_6_28}{\*\bkmkend co_pp_sp_999_6_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*6
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court finds that Cedars\u8211\'3fSinai has adequately identified its trade secrets to permit Quest to prepare a responsive pleading. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Cedars\u8211\'3fSinai describes its trade secrets as \u8220\'3ffinancial, business, scientific, technical, economic, and/or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs, or codes, tangible and/or intangible, related to IBS diagnostic techniques and validation of the same, as well as how to serve unmet clinical needs associated with IBS.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 SAC \u182\'3f 52. As discussed above, Cedars\u8211\'3fSinai also identifies the specific confidential communications that allegedly contain these trade secrets. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 36\u8211\'3f43 (listing confidential communications to Quest during licensing negotiations). This alone limits the scope of Cedars\u8211\'3fSinai\rquote s alleged trade secrets and gives enough detail for Quest \u8220\'3fto prepare a defense and for the court to craft limits on discovery.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041351608&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gatan,
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2017 WL 1196819 at *6
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022360856&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
TMX Funding, Inc. v. Impero Techs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Case No. C 10\u8211\'3f00202\u8211\'3fJF (PVT), 2010 WL 2509979, at *3 (N.D. Cal. June 17, 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). In addition, Cedars\u8211\'3fSinai specifically points out as least two aspects of its trade secrets: \u8220\'3ftwo possible test methods that leverage inventions covered in Cedars\u8211\'3fSinai\rquote s then pending patent applications but are not themselves disclosed in the patent applications, as well as how to validate tests based on the direct measurement of anti\u8211\'3fCdtB and anti-vinculin antibodies and how the same would serve unmet clinical needs\u8221\'3f (SAC \u182\'3f41) and \u8220\'3fconfidential IBS diagnostic market research presentation detailing Cedars\u8211\'3fSinai\rquote s assessment of the market opportunity for its IBS diagnostic technology and strategies for increasing its acceptance and adoption by patients, physicians, and payers. This included highly valuable and sensitive analysis of pricing and adoption strategies for IBS diagnostics\u8221\'3f (SAC \u182\'3f 42). 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036705724&pubNum=0007903&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_7903_1193&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_1193" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
T\u8211\'3fMobile
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 115 F. Supp. 3d at 1193
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding plaintiffs identification of trade secrets adequate because it identified at least two aspects that defendant targeted in its misappropriation). The Court would thus deny the Motion to the extent it seeks to compel a more definite statement regarding Cedars\u8211\'3fSinai\rquote s alleged trade secrets.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b1634c1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b1634c1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b1634c1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b1634c1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
B. Third Claim: Breach of Contract
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Confidentiality Agreement binding the parties provides that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
[Quest] agrees to hold and maintain all of [Cedar\u8211\'3fSinai\rquote s] Proprietary Information in strictest confidence for a period of five (5) years from the [November 5, 2013]. [Quest] shall not reverse engineer, disassemble or decompile any samples, prototypes, software or other tangible objects provided by [Cedar\u8211\'3fSinai] hereunder other than with [Cedar\u8211\'3fSinai\rquote s] express written authorization. [Quest] shall not use any of [Cedar\u8211\'3fSinai\rquote s] Proprietary Information other than for the Purpose; provided that [Quest] shall not be liable to [Cedar\u8211\'3fSinai] with respect to the use or disclosure of such information as can be established by credible evidence to: (a) 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb200 
be publicly known, without fault on [Quest\rquote s] part, subsequent to the disclosure of such information to [Quest].
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Confidentiality Agreement, Docket No. 26\u8211\'3f3, \u182\'3f 2.a (emphasis added). As an extension of the argument the Court has rejected, Quest argues that because the information it allegedly misappropriated was publicly available, Cedars\u8211\'3fSinai has failed to state a claim for breach of contract. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion at 16 (\u8220\'3f[B]y the terms of the Confidentiality Agreement, Quest is not liable for the use of the information disclosed by the PLoS ONE article and patent applications because Cedars\u8211\'3fSinai made that information public. Therefore, Cedars\u8211\'3fSinai\rquote s claim for breach of contract fails as a matter of law because Quest\rquote s activities, as pleaded by Cedars\u8211\'3fSinai, are expressly exempted in the Confidentiality Agreement.\u8221\'3f). For the reasons set forth above, the Court finds that Cedars\u8211\'3fSinai has adequately pleaded that the information provided to Quest included confidential trade secrets and thus rejects Quest\rquote s argument. Accordingly, the Court would deny the Motion in as much as it seeks to dismiss Cedars\u8211\'3fSinai\rquote s third claim for relief.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b187eb1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b187eb1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b187eb1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b187eb1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
C. Fourth Claim: Patent Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
1. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
\sa200 
\sb400 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa200 \sb400 
 and the Asserted Claims
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued July 11, 2017 and is titled \u8220\'3fMethods for Detecting the Presence of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Irritable Bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Syndrome and System for Diagnosing Same.\u8221\'3f The SAC alleges that Quest infringes Claims 3, 4, 9, and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAsserted Claims\u8221\'3f). SAC \u182\'3f 73. The four Asserted Claims recite:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3. A system for diagnosing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 syndrome, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
an isolated biological sample from a subject desiring diagnosis regarding 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 syndrome (IBS); and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
an assay for detecting in the biological sample, a level of an anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
4. The system of claim 3, wherein the assay is an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme-linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (ELISA), wherein the ELISA comprises using vinculin, SEQ ID NO:1 or a fragment thereof as a substrate or reagent to bind the anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
9. A system, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
an isolated biological sample from a subject desiring a diagnosis to distinguish between 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 syndrome (IBS) and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic33f4532475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
inflammatory bowel disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (IBD); and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_7_28}{\*\bkmkend co_pp_sp_999_7_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*7
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 an assay for detecting in the biological sample, a level of anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
10. The system of claim 9, wherein the assay is an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme-linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (ELISA), wherein the ELISA comprises using vinculin, SEQ ID NO:1 or a fragment thereof as a substrate or reagent to bind the anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Quest argues the Asserted Claims are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they are drawn to patent-ineligible subject matter. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion at 16\u8211\'3f23.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b1c0121065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b1c0121065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa200 \sb400 
2. The Mayo/Alice Test for Patent Eligibility Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i1 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i1 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i1 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i1 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i1 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i1 \fs20 \chcbpat2 
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
An invention or a discovery is patentable if it is a \u8220\'3fnew and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fIn choosing such expansive terms ... Congress plainly contemplated that the patent laws would be given wide scope.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_308&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_308" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. 303, 308 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Still, the Supreme Court has identified exceptions to this wide scope to \u8220\'3fdistinguish patents that claim the building blocks of human ingenuity, which are ineligible for patent protection, from those that integrate the building blocks into something more.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_708_2350&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2350" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank Int\rquote l
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. 2347, 2350 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_89&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_89" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.,
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 566 U.S. 66, 89 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (internal quotations omitted). These exceptions to patent protection are \u8220\'3flaws of nature, natural phenomena, and abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_185&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_185" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 185 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While the boundaries of the judicial exceptions remain subject to further development, the Supreme Court has clearly stated the policy underlying those exceptions: avoiding patents that \u8220\'3ftoo broadly preempt the use of a natural law [or abstract idea].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S. Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, patent law should \u8220\'3fnot inhibit further discovery by improperly tying up the future use of laws of nature [or abstract ideas].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court \u8220\'3fset forth a framework for distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The first step is to ask \u8220\'3fwhether the claims at issue are directed to one of those patent-ineligible concepts.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 If not, the claims fall within the scope of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and are patent-eligible. If the claims are directed to one of the exceptions, the next step is to search for an \u8220\'3finventive concept\u8221\'3f that is \u8220\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the natural law itself.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72\u8211\'3f73
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In doing so, a court must \u8220\'3fconsider the elements of each claim both individually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether the additional elements \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 78\u8211\'3f79
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The question in the law of nature context is whether the claims at issue add more than \u8220\'3f \u8216\'3fwell-understood, routine, conventional activity already engaged in by the scientific community\u8217\'3f \u8221\'3f to the law of nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1047&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1047" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1047 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_79&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_79" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 79\u8211\'3f80
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). \u8220\'3f[G]roundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_577&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_577" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\rquote n for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 577 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b206df1065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b206df1065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
3. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa200 \sb400 
 Step One
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_8_28}{\*\bkmkend co_pp_sp_999_8_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Quest argues that the Asserted Claims are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they \u8220\'3fare directed to a single natural phenomenon: the correlation between the presence of anti-vinculin antibodies and IBS.\u8221\'3f Motion at 17. Quest argues, \u8220\'3f[t]he Federal Circuit has found substantively identical claims invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 19 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1361&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1361" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Found. v. True Health Diagnostics, LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d 1352, 1361 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Quest also argues that the Asserted Claims represent a \u8220\'3fsweeping preemption of the natural phenomenon,\u8221\'3f as Claims 3 and 9 \u8220\'3fpreempt all means for detecting the natural phenomenon of elevated vinculin in IBS patients.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 20. Quest argues that Claims 4 and 10 fare no better because \u8220\'3fthe recitation of ELISA to detect anti-vinculin is not sufficiently novel or specific to transform the natural phenomenon into a patent eligible application thereof.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cedars\u8211\'3fSinai argues that Quest fails to prove invalidity of the Asserted Claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Opp\rquote n at 14. Cedars\u8211\'3fSinai first asserts that a person of ordinary skill in the art would understand the term \u8220\'3fan assay\u8221\'3f as used in the claims to mean \u8220\'3fa vinculin\u8211\'3fbased assay.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 15\u8211\'3f16. Cedars\u8211\'3fSinai further contends that, \u8220\'3f[b]ecause vinculin is an intracellular protein, it must first be 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
manufactured
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and isolated in order to prepare the vinculin-based assay of the asserted claims.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 19 (emphasis in original). Cedars\u8211\'3fSinai asserts that \u8220\'3fvinculin utilized in the claimed assay will have different characteristics and will behave differently in the environment of a diagnostic assay than naturally-occurring vinculin would within the cellular environment.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 20. Based on these characterizations, Cedars\u8211\'3fSinai argues the Asserted Claims \u8220\'3fcannot be directed to natural phenomena because they each use a non-naturally occurring component: vinculin.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 21. Cedars\u8211\'3fSinai argues that preemption is not a concern because the Asserted Claims are \u8220\'3flimited specifically to vinculin-based assays.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 22.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In reply, Quest again emphasizes the Federal Circuit\rquote s decision in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Reply at 12. Quest argues the Asserted Claims are invalid even accepting Cedars\u8211\'3fSinai\rquote s construction of \u8220\'3fan assay\u8221\'3f as \u8220\'3fa vinculin\u8211\'3fbased assay.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 15\u8211\'3f16. Quest again compares the Asserted Claims to the claims at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and notes that even though the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims implicated manufactured components in commercially-available tests, the claims were still patent-ineligible because the focus of the claims was detecting MPO levels in the body using known techniques. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 17. Quest argues that even assuming Cedars\u8211\'3fSinai\rquote s construction of \u8220\'3fan assay,\u8221\'3f the preemption analysis does not change because, as Cedars\u8211\'3fSinai represented in its opposition, an assay for detecting a level of anti-vinculin antibody 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fmust necessarily use vinculin as the assay reagent.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 18 (quoting Opp\rquote n at 16).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In analyzing the Asserted Claims, it is helpful to consider and compare other claims that have been tested against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish, LLC v. Microsoft Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d 1327, 1334 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe Supreme Court has not established a definitive rule to determine what constitutes an \u8216\'3fabstract idea\u8217\'3f sufficient to satisfy the first step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry. Rather, both this court and the Supreme Court have found it sufficient to compare claims at issue to those claims already found to be directed to an abstract idea in previous cases.\u8221\'3f (Internal citations omitted).)
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit affirmed a district court\rquote s determination that claims from three patents were invalid because they were not directed to patent-eligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d at 1355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Federal Circuit specifically concluded that the claims were \u8220\'3fdirected to multistep methods for observing the law of nature that MPO [ (myeloperoxidase) ] correlates to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1360&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1360" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1360
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. One of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent claims, for instance, recited:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_9_28}{\*\bkmkend co_pp_sp_999_9_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*9
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 21. A method of assessing the risk of requiring medical intervention in a patient who is presenting with chest pain, comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
characterizing the levels of myeloperoxidase activity, myeloperoxidase mass, or both, respectively in the bodily sample from the human patient, wherein said bodily sample is blood or a blood derivative,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a patient whose levels of myeloperoxidase activity, myeloperoxidase mass, or both is characterized as being elevated in comparison to levels of myeloperoxidase activity, myeloperoxidase mass or both in a comparable bodily samples obtained from individuals in a control population is at risk of requiring medical intervention to prevent the occurrence of an adverse cardiac event within the next six months.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1356\u8211\'3f57 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,459,286
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Other dependent claims of the same patent limited myeloperoxidase (\u8220\'3fMPO\u8221\'3f) detection \u8220\'3fby flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and further require[d] detection of another compound, troponin.\u8221\'3f In concluding particular independent patent claims were representative, the Federal Circuit noted that the dependent claims in the three patents \u8220\'3fmerely recite[d] known methods of detecting MPO or MPO derivatives and applie[d] the correlation between these biomarkers and cardiovascular health.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1360. The Federal Circuit noted that the plaintiff \u8220\'3fhas not created a new laboratory technique; rather, it uses well-known techniques to execute the claimed method. The specification of the testing patents confirm that known testing methods could be used to detect MPO, and that there were commercially available testing kits for MPO detection.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1361.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Asserted Claims in this matter appear initially to be highly analogous to the claims invalidated by the Federal Circuit in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Asserted Claims essentially recite the combination of an assay for detecting an anti-vinculin antibody and a biological sample \u8220\'3ffrom a subject desiring diagnosis\u8221\'3f of IBS. The crux of the claims thus relies on the fact that there is a correlation between IBS and a subject\rquote s levels of anti-vinculin antibody. In other words, the claims are directed to systems for observing the law of nature that anti-vinculin antibody correlates to IBS.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This conclusion at 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step 1 is not impacted by Cedars\u8211\'3fSinai\rquote s argument that the claim phrase \u8220\'3fan assay\u8221\'3f in the Asserted Claims must be construed as \u8220\'3fa vinculin\u8211\'3fbased assay.\u8221\'3f 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Assuming the claim term \u8220\'3fan assay\u8221\'3f means \u8220\'3fa vinculin-based assay,\u8221\'3f and even further assuming the claimed vinculin-based assay utilizes manufactured or non-naturally-occurring vinculin, does not change the analysis. The focus of the Asserted Claims is not on the assay itself, but on the system\rquote s goal of diagnosing IBS. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Claim 3 (\u8220\'3fA system for diagnosing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 syndrome, comprising ...\u8221\'3f). Whether the system can diagnose IBS, in turn, is dependent on the correlation between IBS and anti-vinculin antibody. This core law of nature persists even where the claimed diagnostic assay is a vinculin-based assay. Cedars\u8211\'3fSinai attempts to distinguish 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and other cases on the basis that the Asserted Claims \u8220\'3fprovide a vinculin-based assay that utilizes ... non-naturally occurring components, and the subject vinculin and anti-vinculin antibody were not known or expected to be predictive of IBS in assays.\u8221\'3f Opp\rquote n at 22\u8211\'3f23 n.8. But this argument is an exercise in misdirection. Like the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims, the Asserted Claims \u8220\'3fpurport[ ] to detect naturally-occurring [anti-vinculin antibodies] through well-known techniques based on a known correlation between [anti-vinculin antibodies] and the disease state.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Cedars\u8211\'3fSinai\rquote s parenthetical describing patents at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_1362&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1362" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d at 1362
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fCleveland Clinic does not purport to have invented colorimetric-based assay, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, or ELISA, or any of the claimed methods to \u8216\'3fsee\u8217\'3f MPO and its derivatives in bodily samples. Rather, the claims here instruct that MPO levels be detected or determined using any of these known techniques.\u8221\'3f). Specifically, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states, \u8220\'3f[o]ne of ordinary skill in the art will readily appreciate methods and systems that can be used to detect the presence or absence of an antibody that binds specifically to vinculin, SEQ ID NO: 1 or a fragment thereof. These methods and systems include but are not limited to ELISA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad314d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunohistochemistry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iaf7c5e9d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
fluorescence in situ hybridization
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (FISH), radioimmuno assays, and affinity purification.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 12:28\u8211\'3f36.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_10_28}{\*\bkmkend co_pp_sp_999_10_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*10
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The fact that the correlation between vinculin and IBS was not known before Cedars\u8211\'3fSinai\rquote s discovery is also irrelevant. As a law of nature, this correlation has always existed. Simply because Cedars\u8211\'3fSinai was the first to discover it, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, make a \u8220\'3fbreakthrough\u8221\'3f in the field, does not change its inherent character as a law of nature. For this reason, any attempt by Cedars\u8211\'3fSinai to distinguish 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 based on the argument that the correlation between MPO and cardiovascular health was already known before 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic\rquote s
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent issued is also unpersuasive. As stated, \u8220\'3fgroundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_780_577&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_577" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad Genetics
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 577
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Accordingly, the Asserted Claims are directed to a law of nature under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step One.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Importantly, as Quest noted in its reply, Cedars\u8211\'3fSinai has represented that \u8220\'3f \u8216\'3fan assay for detecting ... a level of anti-vinculin antibody\u8217\'3f must necessarily use vinculin as the assay reagent.\u8221\'3f Opp\rquote n at 16; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Reply at 18. If Cedars\u8211\'3fSinai\rquote s position is accepted, under Cedars\u8211\'3fSinai\rquote s own interpretation of the claims, any assay relying on detecting anti-vinculin antibodies in order to diagnose IBS would be covered by the claims. In other words, the Asserted Claims, and particularly Claims 3 and 9, would preempt all assays detecting a correlation between anti-vinculin antibody and IBS. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Such sweeping preemption concerns confirm the nature of the Asserted Claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S. Ct. at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (patent law should \u8220\'3fnot inhibit further discovery by improperly tying up the future use of laws of nature.\u8221\'3f). At the first hearing on the Motion, counsel for Cedars\u8211\'3fSinai argued that preemption is not a concern because while the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 covers vinculin-based assays, it does not cover using CdtB assays to diagnose vinculin. As counsel for Quest correctly noted, however, the question of preemption asks whether a particular law of nature is tied up by the patented invention. Simply pointing to a different law of nature (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the correlation between CdtB and IBS as opposed to the correlation between vinculin and IBS) does not address the issue. At the supplemental hearing on the Motion, Cedars\u8211\'3fSinai shifted its argument and stated that the Asserted Claims do not preempt the correlation between anti-vinculin antibodies and IBS, in part because, according to Cedars\u8211\'3fSinai, manufactured vinculin has only a single, specific amino acid sequence. Cedars\u8211\'3fSinai\rquote s shifting approach will be addressed in the next section, but it is worth noting that again, if true that manufactured vinculin only has a single, specific amino acid sequence, then preemption would remain a problem as others would still be unable to use any vinculin-based assay (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the only available type of vinculin-based assay) to diagnose IBS.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court concludes that the claims are directed to a law of nature under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step 1 and thus proceeds to analyze 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step 2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b2fb031065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b2fb031065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
5. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa200 \sb400 
 Step Two
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In its Motion, Quest argued that the Asserted Claims fail 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two because \u8220\'3fthere is no \u8216\'3finventive concept\u8217\'3f beyond the natural phenomenon.\u8221\'3f Motion at 22; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fIndeed, at no point, either in the patent specification or during prosecution did Cedars\u8211\'3fSinai argue that an assay for anti-vinculin antibodies was novel.\u8221\'3f) Similar to its arguments in its Opposition under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step One, Cedars\u8211\'3fSinai argued the Asserted Claims are patentable under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two \u8220\'3fbecause the claimed vinculin-based assay constitutes a new and unique way of improving IBS diagnoses.\u8221\'3f Opp\rquote n at 23. Cedars\u8211\'3fSinai appeared to focus its argument on the idea that the claimed assay was specifically a \u8220\'3fvinculin-based assay\u8221\'3f and noted that claim construction was necessary to construe the term. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 15. It emphasized that the vinculin used in the assays had to be manufactured and thus the Asserted Claims could not be directed toward natural phenomena. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 19. In reply, Quest argued, \u8220\'3f[i]t may be that testing for anti-vinculin is a new way of diagnosing IBS, but even if it is, and even if that discovery were \u8216\'3fpioneering,\u8217\'3f it does not constitute a patent-eligible concept because that application of a natural phenomenon was achieved using a conventional assay long known in the prior art.\u8221\'3f Reply at 20.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_11_28}{\*\bkmkend co_pp_sp_999_11_28}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*11
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 At the first hearing on Quest\rquote s Motion, held on February 12, 2018, Cedars\u8211\'3fSinai again initially appeared to be focusing the bulk of its argument on the idea that the claim term \u8220\'3fan assay\u8221\'3f referred to \u8220\'3fa vinculin-based assay\u8221\'3f that uses manufactured vinculin. However, over the course of oral argument, Cedars\u8211\'3fSinai began adding further emphasis to an argument that the Asserted Claims recite an inventive concept because vinculin-based assays were purportedly not well-understood, routine, or conventional at the time of filing of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Cedars\u8211\'3fSinai argued that as emphasized in recent Federal Circuit opinions, whether something is routine, conventional, or well-understood is a question of fact. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043776259&pubNum=0000999&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Berkheimer v. HP Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f F.3d \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 2018 WL 774096 (Fed. Cir. Feb. 8, 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Notably, in its opposition, Cedars\u8211\'3fSinai specifically did not raise this argument and indeed, failed to respond to Quest\rquote s arguments that vinculin-based assays were well-known in the art at the time of filing of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 12\u8211\'3f25.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
At the supplemental hearing on Quest\rquote s Motion held on February 15, 2018, Cedars\u8211\'3fSinai once again argued that vinculin-based assays were not well-known in the art. Cedars\u8211\'3fSinai distinguished 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in part based on this fact, arguing that the MPO testing kits covered by the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims were available on the market before the patent was filed. Cedars\u8211\'3fSinai reiterated the argument that claim construction of the term \u8220\'3fassay\u8221\'3f is necessary in determining whether the Asserted Claims recite an inventive concept.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court is concerned by what appears to be a \u8220\'3fshifting sands\u8221\'3f approach on Cedars\u8211\'3fSinai\rquote s part as to its 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 arguments. Indeed, the Court notes that Cedars\u8211\'3fSinai\rquote s arguments about the non-routine and unconventional nature of manufactured, vinculin-based assays are not reflected in its SAC.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties\u8217\'3f arguments in briefing and at oral argument, however, lead the Court to conclude that expedited claim construction and expedited claim construction discovery as to the claim term \u8220\'3fan assay\u8221\'3f would be beneficial before the Court reaches a determination as to patentability under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat30 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00072044666998_ID0EANAI_28}{\*\bkmkend co_fnRef_B00072044666998_ID0EANAI_28}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00072044666998_28" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
7
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Accordingly, the Court would DENY Quest\rquote s Motion to Dismiss WITHOUT PREJUDICE as to the patent-eligibility of Claims 3, 4, 9, and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The parties would be ORDERED to meet and confer regarding an expedited discovery and claim construction schedule solely as it relates to the claim term \u8220\'3fan assay\u8221\'3f as it appears in Claims 3, 4, 9, and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b34b941065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b34b941065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4b34b941065711ebaa7ffd5d04541}{\*\bkmkend co_anchor_I4b34b941065711ebaa7ffd5d04541}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
IV. Conclusion
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Based on the foregoing discussion, the Court would DENY the Motion as to Cedars\u8211\'3fSinai\rquote s First, Second, and Third causes of action. The Court would DENY Quest\rquote s Motion to Dismiss WITHOUT PREJUDICE as to the patent-eligibility of Claims 3, 4, 9, and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The parties would be ORDERED to meet and confer regarding an expedited discovery and claim construction schedule solely as it relates to the claim term \u8220\'3fan assay\u8221\'3f as it appears in Claims 3, 4, 9, and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_28}{\*\bkmkend co_allCitations_28}
{\b1 \cf18 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not Reported in Fed. Supp., 2018 WL 2558388
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012044666998_28}{\*\bkmkend co_footnote_B00012044666998_28}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012044666998_ID0EQHAC_28" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The transmission of this presentation would seem to predate the execution of the Confidentiality Obligations. 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Compare
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 SAC \u182\'3f 
}
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat30 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat30 
{\b1 \cf19 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf1 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (Confidentiality Obligations entered into on or about November 24, 2013) 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
with
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 SAC \u182\'3f 36 (confidential presentation sent on or about November 13, 2013).
\par 
}
}
}
}
}\b0 \cf1 \f3 \strike0 \i0 \fs18 \sa0 \sb0 \ri0 \ul0 \qj \li0 \chcbpat2 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022044666998_28}{\*\bkmkend co_footnote_B00022044666998_28}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022044666998_ID0EQLAE_28" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The parties similarly analyze these two claims together. 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Motion at 8\u8211\'3f15; Opp\rquote n at 3\u8211\'3f12.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032044666998_28}{\*\bkmkend co_footnote_B00032044666998_28}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032044666998_ID0EF1AE_28" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
As explained below, the Court finds that Cedars\u8211\'3fSinai adequately pleads its first, second, and third claims and that relief is not warranted under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Rule 12(b)(6) or Rule 12(e)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. This was not a close call and, even were the Court to apply a heightened pleading standard, it would find that Cedars\u8211\'3fSinai has described its trade secrets with \u8220\'3freasonable particularity.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042044666998_28}{\*\bkmkend co_footnote_B00042044666998_28}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042044666998_ID0E62AE_28" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In deciding a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Rule 12(b)(6)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 motion, a court \u8220\'3fmay generally consider only allegations contained in the pleadings, exhibits attached to the complaint, and matters properly subject to judicial notice.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011437883&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_763&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_763" }{\fldrslt 
{\b0 \cf23 \f3 \i1 \fs18 
{\b0 \cf23 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Swartz
}
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 476 F.3d at 763
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. The court may also consider material necessarily relied on by the complaint. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001385224&pubNum=0000506&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=RP&fi=co_pp_sp_506_688&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_688" }{\fldrslt 
{\b0 \cf23 \f3 \i1 \fs18 
{\b0 \cf23 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Lee v. City of Los Angeles
}
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 250 F.3d 668, 688\u8211\'3f89 (9th Cir. 2001)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. The SAC includes the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f884 Patent
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 as an exhibit (SAC, Exhibit A) and specifically refers to the patent applications (SAC \u182\'3f\u182\'3f 33, 41, 43, 74\u8211\'3f75), the PLoS One article (SAC \u182\'3f 15), and Quest\rquote s trademark application (SAC \u182\'3f 47). Accordingly, the Court will consider those materials in its analysis of the Motion. The other materials that Quest asks the Court to consider are not generally known within the Court\rquote s jurisdiction or capable of accurate and ready determination from sources whose accuracy cannot reasonably be questioned and thus the Court declines to take judicial notice and consider those materials. 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000607&cite=USFRER201&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Federal Rule of Evidence 201(b)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052044666998_28}{\*\bkmkend co_footnote_B00052044666998_28}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052044666998_ID0EPCAG_28" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
As just one example of these highly factual issues, the parties disagree as to the meaning of \u8220\'3fas of and before July 9, 2015\u8221\'3f and whether Quest used confidential trade secret information from Cedars\u8211\'3fSinai before that date. SAC \u182\'3f 47; Motion at 7. Cedars\u8211\'3fSinai alleges that \u8220\'3fas of and before July 9, 2015, Quest was creating, designing, developing, and/or using an IBS assay and/or doing IBS testing and/or making preparations for delivery of IBS services and the use of an IBS assay or diagnostic.\u8221\'3f SAC \u182\'3f 47. Whether or not Quest actually used confidential information from Cedars\u8211\'3fSinai before that date is a question for the fact\u8211\'3ffinder, not for the Court on a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I9d72eec0688e11e88808c81b5a222cba&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Rule 12(b)(6)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 motion.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00062044666998_28}{\*\bkmkend co_footnote_B00062044666998_28}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00062044666998_ID0EFHAG_28" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The appropriate pleading standard as to trade secret claims is discussed in a preceding section. The Court notes that even if it applies a heightened \u8220\'3freasonable particularity\u8221\'3f standard, Cedars\u8211\'3fSinai\rquote s description of its trade secrets would suffice.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00072044666998_28}{\*\bkmkend co_footnote_B00072044666998_28}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00072044666998_ID0EANAI_28" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
7
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
It is this Court\rquote s practice during claim construction to require each party to explain what effect, if any, its proposed claim construction will have on the case if adopted. Particularly in this case, the parties will be expected to describe how their proposed constructions will influence questions relating to patent-eligibility, anticipation, obviousness, enablement, and non-infringement.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf25 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf25 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf25 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf25 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf25 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }